PLRZ today
$11.59-$0.12 (-1.02%)close Nov 6, 2026Trend
DailyDowntrend (starting)
4 hourStrong Bullish
1 hourStrong Bullish
15 minSymmetric Triangle
5 minStrong Bearish
Daily trend turns up above $1857.30
Key levels
Resistance$13.89
Resistance$12.34
Support$10.32
Support$8.38
Latest news & SEC filings
ProductPolyrizon finishes patient enrollment in NASARIX clinical study
ProductPolyrizon finishes enrolling participants in NASARIX trial for airborne allergens
All PLRZ news →About Polyrizon
Polyrizon is a clinical-stage biotech company based in Israel that develops nasal products. Its lead candidates use a Capture and Contain technology to block allergens and viruses from reaching nasal tissue, while a Trap and Target platform delivers active drugs through the nose. The company is developing these products for patients and healthcare providers, and it operates primarily in Israel and the United States.
Based on the company's 20-F filed Mar 25, 2026.
Nasdaq · Healthcare
Polyrizon Ltd. (PLRZ)
What Is the Price Target for PLRZ?
SEPT Low Target
$0.00
SEPT Mid Target
$0.00
SEPT High Target
$0.00
Analyst Consensus
$0.00
Is PLRZ a Buy or Sell Right Now?
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for PLRZ.
Start Free Trial →Is PLRZ Overvalued or Undervalued?
Valuation Verdict
N/A
Methods Used
N/A
Fair Value
$N/A
5
Moat Score
NONE
0/9
Piotroski Score
N/A
Altman Z-Score
What Is Smart Money Doing with PLRZ?
Insider Signal
NEUTRAL
0 buys / 3 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →PLRZ Growth Story
Revenue YoY
N/A%
3yr Revenue CAGR
N/A%
EPS Growth YoY
N/A
FCF Growth YoY
N/A%
Revenue Trend
UNKNOWN
Dark Pool Trades for PLRZ
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for PLRZ, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 17:28:58 | $11.45 | 2,000 | $$23K | SELL |
| 16:48:21 | $11.45 | 1,300 | $$15K | SELL |
| 20:58:51 | $11.15 | 5,811 | $$65K | SELL |
| 14:48:26 | $11.30 | 5,000 | $$57K | BUY |
| 19:10:51 | $10.49 | 3,500 | $$37K | BUY |
5 dark pool trades shown · $$196K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Polyrizon Ltd. (PLRZ) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings intelligence, and a complete investment thesis with entry and exit recommendations.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →PLRZ — frequently asked questions
What is PLRZ stock price today?
Polyrizon Ltd. (PLRZ) is at $11.59, down 1.02% (-$0.12) at the Nov 6, 2026 close.
Why is PLRZ stock moving today?
Latest PLRZ news — Oct 28, 2026: Polyrizon finishes patient enrollment in NASARIX clinical study · Oct 27, 2026: Polyrizon finishes enrolling participants in NASARIX trial for airborne allergens
What are PLRZ support and resistance levels?
Support: $10.32, $8.38, $6.39. Resistance: $12.34, $13.89, $15.34.
What are insiders doing with PLRZ?
Insider activity: NEUTRAL, 0 buys and 3 sells in the last 90 days.
What is the latest news on PLRZ?
Oct 28, 2026: Polyrizon finishes patient enrollment in NASARIX clinical study · Oct 27, 2026: Polyrizon finishes enrolling participants in NASARIX trial for airborne allergens